Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs BILTRICIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Treatment of schistosomiasis (all species),Treatment of clonorchiasis sinensis (liver fluke),Treatment of opisthorchiasis (liver fluke),Off-label: Treatment of neurocysticercosis (in combination with corticosteroids),Off-label: Treatment of other trematode infections (e.g., fasciolopsiasis, intestinal flukes),Off-label: Treatment of cestode infections (e.g., diphyllobothriasis, taeniasis)
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Extensively metabolized by the liver, primarily by cytochrome P450 enzymes (CYP3A4), to inactive hydroxylated metabolites.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
~93% bound to plasma proteins, primarily albumin.
Approximately 80-85% bound to serum albumin.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution.
Oral: ~33% due to extensive first-pass metabolism.
Oral bioavailability is approximately 80% due to extensive first-pass metabolism; higher with food.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
No dosage adjustment required for any degree of renal impairment.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
No specific Child-Pugh based adjustments; contraindicated in hepatocellular carcinoma or history of hepatic encephalopathy; use caution in severe liver disease.
Not recommended for use in children under 15 years old; safety and efficacy not established.
4 years and older: 60 mg/kg/day in 3 divided doses for 1 day; maximum single dose 2 g.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
No specific adjustments; use standard adult dosing with monitoring for adverse effects.
None
None.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Avoid grapefruit juice during treatment due to increased praziquantel exposure.,May cause transient neurologic symptoms in patients with cerebral schistosomiasis or neurocysticercosis due to inflammatory reaction around dying parasites.,Use with caution in patients with hepatic impairment (Child-Pugh class B or C) as metabolism may be reduced.,May exacerbate cysticercosis if used without corticosteroids in neurocysticercosis.,Potential for cardiac arrhythmias in patients with ventricular arrhythmias or electrolyte disturbances (rare).
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Hypersensitivity to praziquantel or any component of the formulation,Ocular cysticercosis (due to risk of irreversible ocular damage from inflammatory response),Concurrent use with rifampin (significantly reduces praziquantel plasma concentrations),Children under 1 year of age (safety not established)
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Take with food to enhance bioavailability. Avoid grapefruit juice as it may increase drug levels. Alcohol may worsen CNS side effects and is not recommended.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major malformations reported. Avoid in first trimester unless essential; use in second/third trimester if benefit outweighs risk.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Praziquantel is excreted into breast milk in small amounts; M/P ratio not established. After a single dose, milk levels low; consider pumping and discarding milk for 24-48 hours post-dose. Use with caution in nursing mothers.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
No dose adjustment required for pregnancy; standard dosing (20 mg/kg three times daily for 1 day) unless hepatic impairment present. Pharmacokinetics in pregnancy not significantly altered; unchanged recommendations.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Administer with food to increase absorption and reduce GI side effects. Use with caution in hepatic impairment; dose adjustment may be necessary. Monitor for neuropsychiatric effects (e.g., dizziness, headache) especially in patients with CNS involvement of schistosomiasis. Avoid in patients with ocular cysticercosis due to risk of intraocular inflammation; treat ocular lesions first with corticosteroids.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Take this medication with a meal to improve absorption and reduce stomach upset.,Do not chew or crush the tablets; swallow them whole.,Complete the full course of treatment even if you feel better.,You may experience dizziness, drowsiness, or headache; avoid driving or operating heavy machinery until you know how the drug affects you.,Inform your doctor if you have liver disease or are taking other medications.,Contact your doctor if you experience severe headache, seizures, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs BILTRICIDE, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. BILTRICIDE is a Anthelmintic that works by Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and BILTRICIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of BILTRICIDE is: 60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and BILTRICIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . BILTRICIDE is classified as Category C. Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.